Table 2 Association between miR-100 expression and clinicopathological parameters of bladder cancer
From: Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer
Clinical features | N | miR-100 | P | |
|---|---|---|---|---|
Low (n = 78) | High (n = 48) | |||
Sex | ||||
Male | 87 | 55 (63.2) | 32 (36.8) | 0.1 |
Female | 39 | 23 (59.0) | 16 (40.9) | |
Age (years) | ||||
≤70 | 55 | 30 (54.5) | 25 (45.5) | 0.08 |
>70 | 71 | 48 (67.6) | 23 (32.4) | |
Stage | ||||
Ta | 48 | 20 (41.7) | 28 (58.3) | 0.01 |
T1 | 46 | 30(65.2) | 16 (34.8) | |
≥T2 | 32 | 28 (87.5) | 4 (12.5) | |
Grade | ||||
LMP | 32 | 20 (62.5) | 12 (37.5) | 0.2 |
LG | 43 | 26(60.5) | 17(39.5) | |
HG | 51 | 32(62.7) | 19(37.3) | |
Carcinoma in situ | ||||
Yes | 26 | 18 (69.2) | 8(30.8) | 0.09 |
No | 100 | 60 (60.0) | 40 (40.0) | |
Recurrence | ||||
Yes | 43 | 36(83.7) | 7 (16.3) | 0.008 |
No | 73 | 42 (57.5) | 31(42.5) | |
Progression | ||||
Yes | 26 | 20 (76.9) | 6 (23.1) | 0.01 |
No | 100 | 58 (58.0) | 42(42.0) | |
Death | ||||
Yes | 65 | 62 (95.4) | 3 (4.6) | < 0.001 |
No | 61 | 16 (26.2) | 45 (73.8) | |